Shanghai Pharmaceutical (Group) Co., Ltd | Company profile from Hoover's

Search History:
Call Now! 8664643156
More information - down arrow - for alternative
Sign Up for Hoover's
Unlimited
Subscription Site
button - learn more - alternatebutton - free trial - alternate

Video Center

Shanghai Pharmaceutical (Group) Co., Ltd · Shanghai China

Company Description

200 Tai Cang Rd.
Shanghai
200020
China (Map)
Phone: +86-21-6373-0908
Fax: +86-21-6374-8398
Need a detailed report
on this company?
button - Buy report - alternate
    Shanghai Pharmaceutical Group, or SPGC, knows that Big Pharma is big business. One of China's largest pharmaceutical companies, SPGC makes over-the-counter (OTC) medicines, prescription drugs, active pharmaceutical ingredients (APIs), biopharmaceuticals, and traditional Chinese medicine. The vertically-integrated company distributes its wares and owns more than 1,000 retail locations. SPGC sells drugs in 30 countries from five foreign offices. Its R&D facility, Central Research Institute, operates 10 centers across China. In 1996 many small producers, including Sine, Dragon & Tiger, and Pioneer, merged to form SPGC. To read the full description, subscribe now.
    Call Now at 8664643156 or Click here for a Free Hoover's Trial!

    Shanghai Pharmaceutical (Group) Co., Ltd Reports

    No subscription, no problem.
    Download presentation-ready reports for this company now.
    From company profiles to the competitive landscape, Hoover’s offers immediate access to individual reports.

    Key Shanghai Pharmaceutical (Group) Co., Ltd Financials

    Company TypePublic

    Headquarters
    2009 Employees2,408

    Shanghai Pharmaceutical (Group) Co., Ltd Executives

    9 executives listed for Shanghai Pharmaceutical (Group) Co., Ltd's Shanghai China location.
    TitleName & BioContact
    PresidentWu JianwenEmail
    CFOZhao DachuanEmail
    VPYang Su MingEmail

    Competition

    Sponsored Links

    Persistent Footer SeperatorPersistent Footer SeperatorHoovers - A D&B CompanySign Up For Our Unlimited Subscription SiteBuy This Report